Get access. Get started. Stay supported
At TZIELD COMPASS, we will provide support to help ensure a smooth treatment experience with TZIELD.
Through our personalized program, patients will receive helpful tools and resources, information about financial assistance options, and additional support from the day of enrollment. Our team can also provide important reimbursement information and further education about TZIELD.

TZIELD COMPASS is a patient support program that helps eligible patients to gain access to TZIELD and provides them with education and resources related to TZIELD.
A person flying a small airplane
COMPASS Navigators: support at every step
A COMPASS Navigator will be there for your patient throughout their treatment with TZIELD. As an important resource throughout your patient’s treatment with TZIELD, the COMPASS Navigator can:
Help navigate the steps to product access, including prior authorizations, medical exceptions, appeals, and reauthorizations
Support you and your patient in locating site of care options for TZIELD infusions depending on their insurance and other factors
Offer education on product procurement through specialty pharmacy or Buy and Bill, as well as information about reimbursement
Perform additional check-ins with your patient once treatment is completed
Explain how insurance benefits work to your patient and help them determine their potential out-of- pocket costs
Answer any questions about the program and offerings
Provide information about financial assistance options that may be available to your patients, like the TZIELD Copay Program and Patient Assistance Program (PAP)
The TZIELD COMPASS Copay Program provides assistance to eligible* commercially insured patients.
Eligible patients may pay as little as $0 for TZIELD.
Copay information and online enrollment
Your patients may be able to save on out-of-pocket costs for TZIELD.

With the TZIELD COMPASS Copay Program,* commercially or privately insured individuals may pay as little as $0 for TZIELD.

If your patient qualifies, their COMPASS Navigator can help enroll them into the program so they may be able to lower their out-of-pocket costs.
To enroll your patient in TZIELD COMPASS, you will each fill out a section of the START form. Once the form is completed, you can submit it to enroll your patient in the program.
*Eligibility requirements and terms and conditions apply. See for more information. This program is intended to help with the cost of TZIELD and its infusion administration only. It does not help with the cost of other medicines patients take at the same time as TZIELD or with other facility fees.
Talk to your patient about enrolling in TZIELD COMPASS
call (1-844-778-2246, Monday through Friday, 8 AM–8 PM ET] for more information.
Additional resources for download
TZIELD COMPASS Enrollment Support
Guidance for Completing the TZIELD COMPASSTM Patient Start Form
A detailed version of the Patient START Form that provides directions for how to successfully complete the enrollment form.
Prior Authorization (PA) Checklist
A checklist to help ensure you and your practice understand potential health plan prior authorization criteria to help prevent rejections and unnecessary delays.
Sample Letter of Medical Necessity Template
A resource that provides tips to help you draft a sample letter of necessity for your patients. A sample letter is provided for reference.
Sample Letter of Appeal Template
A resource that provides tips to help you draft a letter of appeal for your patients. A sample letter is provided for reference.
Financial Assistance
Copay Assistance Guide
Detailed instructions on how to submit a patient copay claim and how patients can enroll in the copay program.
TZIELD Coding and Billing
Sample Coding
A quick reference sheet, including sample codes, related to coding and billing for TZIELD and its administration.
Coding and Billing Information for TZIELD® (teplizumab-mzwv)
A detailed guide with helpful information related to coding and billing for TZIELD and its administration.
Product Distribution and Ordering Information
Distribution Information for TZIELD® (teplizumab-mzwv)
A document that includes information about distribution of TZIELD and how to order it.
Considerations for TZIELD Infusions at Home
A document that has considerations for placing a supply order for TZIELD infusions at home.
Important Safety Information
TZIELD is a CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D.
  • Cytokine Release Syndrome (CRS): CRS occurred in TZIELD-treated patients during the treatment period and through 28 days after the last drug administration. Prior to TZIELD treatment, premedicate with antipyretics, antihistamines and/or antiemetics, and treat similarly if symptoms occur during treatment. If severe CRS develops, consider pausing dosing for 1 day to 2 days and administering the remaining doses to complete the full 14-day course on consecutive days; or discontinue treatment. Monitor liver enzymes during treatment. Discontinue TZIELD treatment in patients who develop elevated alanine aminotransferase or aspartate aminotransferase more than 5 times the upper limit of normal (ULN) or bilirubin more than 3 times ULN.
  • Serious Infections: Use of TZIELD is not recommended in patients with active serious infection or chronic infection other than localized skin infections. Monitor patients for signs and symptoms of infection during and after TZIELD administration. If serious infection develops, treat appropriately, and discontinue TZIELD.
  • Lymphopenia: Lymphopenia occurred in most TZIELD-treated patients. For most patients, lymphocyte levels began to recover after the fifth day of treatment and returned to pretreatment values within two weeks after treatment completion and without dose interruption. Monitor white blood cell counts during the treatment period. If prolonged severe lymphopenia develops (<500 cells per mcL lasting 1 week or longer), discontinue TZIELD.
  • Hypersensitivity Reactions: Acute hypersensitivity reactions including serum sickness, angioedema, urticaria, rash, vomiting and bronchospasm occurred in TZIELD-treated patients. If severe hypersensitivity reactions occur, discontinue TZIELD and treat promptly.
  • Vaccinations: The safety of immunization with live-attenuated (live) vaccines with TZIELD-treated patients has not been studied. TZIELD may interfere with immune response to vaccination and decrease vaccine efficacy. Administer all age-appropriate vaccinations prior to starting TZIELD.
    • Administer live vaccines at least 8 weeks prior to treatment. Live vaccines are not recommended during treatment, or up to 52 weeks after treatment.
    • Administer inactivated (killed) vaccines or mRNA vaccines at least 2 weeks prior to treatment. Inactivated vaccines are not recommended during treatment or 6 weeks after completion of treatment.
Most common adverse reactions (>10%) were lymphopenia, rash, leukopenia, and headache.
  • Pregnancy: May cause fetal harm.
  • Lactation: A lactating woman may consider pumping and discarding breast milk during and for 20 days after TZIELD administration.
Please see full Prescribing Information, including patient selection criteria, and Medication Guide. View Important Safety Information page.